PRESS RELEASE AB SCIENCE ANNOUNCES THAT HEALTH CANADA HAS GRANTED ELIGIBILITY FOR RECONSIDERATION REQUEST FOR MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS Paris, 3 April, 2024, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today announces that Health Canada has granted eligibility for reconsideration request for masitinib in amyotrophic lateral sclerosis (ALS). The reconsideration process will re-examine, with new assessors, the decision based on information that was included in the...
PRESS RELEASE TWO NEW FINANCIAL ANALYSIS FIRMS INITIATE COVERAGE OF AB SCIENCE Paris, March 6, 2024, 8.15pm CET AB Science SA (Euronext - FR0010557264 - AB) announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated the coverage of the Company. DNA Finance estimates that AB Science stands out as a compelling investment opportunity in the biotech sector. In Extenso has initiated a strong buy opinion on the share. These new coverages aim to strengthen the AB...
PRESS RELEASE AB SCIENCE ANNOUNCES THAT HEALTH CANADA HAS ISSUED A NOTICE OF NON-COMPLIANCE-WITHDRAWAL (NON/w) FOR MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS AB SCIENCE INTENDS TO SUBMIT A REQUEST FOR RECONSIDERATION Paris, 26 February, 2024, 6.15pm CET AB Science SA (Euronext - FR0010557264 - AB) today announces that Health Canada has issued a Notice of Non-Compliance-Withdrawal (NON/w) regarding its New Drug Submission (NDS) for masitinib in the treatment of amyotrophic lateral sclerosis...
PRESS RELEASE AB SCIENCE ANNOUNCES AN UPDATE IN THE MARKETING AUTHORIZATION APPLICATION OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS AT THE EUROPEAN MEDICINES AGENCY A DECISION FROM THE EUROPEAN MEDICINES AGENCY IS EXPECTED DURING THE SECOND QUARTER OF 2024 Paris, 26 January, 2024, 6pm CET AB Science SA (Euronext – FR0010557264 – AB) announced that the Committee for Medicinal Products for Human Use (CHMP) has proposed that AB Science submit a written response to the List of Outstanding...
PRESS RELEASE THE CLINICAL DEVELOPMENT OF MASITINIB IN SICKLE CELL DISEASE, A HIGHLY PREVALENT GENETIC CONDITION, IS AMONG THE 19 WINNING PROJECTS UNDER THE SIXTH CALL FOR "HOSPITAL-UNIVERSITY RESEARCH IN HEALTH (RHU)". THIS PROGRAM WILL FUND A MASITINIB PHASE 2 CLINICAL TRIAL AB SCIENCE WILL HOLD A WEBCAST ON THIS RESEARCH PROGRAM ON THURSDAY, NOVEMBER 30, 2023, FROM 3PM TO 4PM CET Paris, November 27, 2023, 8am CET AB Science SA (Euronext - FR0010557264 - AB) announces today that a new clinical...
PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE EUROPEAN MEDICINES AGENCY'S TIMETABLE FOR EXAMINATION OF THE MARKETING AUTHORIZATION APPLICATION OF MASITINIB IN AMYOT RO PHIC LATERAL SCLEROSIS BASED ON THE UPDATED TIMETABLE, A DECISION FROM THE EUROPEAN MEDICINES AGENCY IS EXPECTED DURING THE FIRST QUARTER OF 2024 Paris, 18 September , 202 3 , 6pm CET AB Science SA (Euronext – FR0010557264 – AB) today provided an update on the European Medicines Agency’s (EMA) Committee for Medicinal...
PRESS RELEASE AB SCIENCE ANNOUNCES ISSUANCE OF A CANADIAN PATENT FOR MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) WITH PROTECTION UNTIL 203 7 CANADIAN PATENT COMPLETES INTELLECTUAL PROPERTY COVERAGE F OR ALS ACROSS ALL KEY GEOGRAPHIC AREAS WHERE MASITINIB COULD BE MARKETE D, INCLUDING EUROPE, USA , CHINA, JAPAN AND SOUTH KOREA Paris, 1st June , 202 3 , 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today announced that the patent office of Canada has issued a Notice of...
PRESS RELEASE AB SCIENCE SUMMARIZES KEY MESSAGES FROM ITS PARTICIPATION TO A PANEL DISCUSSION AT THE 202 3 ALS DRUG DEVELOPMENT SUMMIT (BOSTON, USA) Paris, 17 May , 202 3 , 8 :00 pm CET AB Science SA (Euronext – FR0010557264 – AB) today summarizes the key messages delivered to an audience of key opinion leaders and decision-makers in the field of ALS research and healthcare policy, during an Panel Discussion at the ALS Drug Development Summit in Boston, USA (May 16-18, 2023). The Annual ALS...
PRESS RELEASE AB SCIENCE SUMMARIZES THE PRESENTATION ON MASITTINIB IN AMYOTROPHIC LATERAL SCLEROSIS MADE A T THE AMERICAN ACADEMY OF NEUROLOGY 2023 ANNUAL MEETING , INCLUDING LONG-TERM SURVIVAL ANALYS IS AND NEW ANALYSIS OF PATIENT POPULATION WITH NO COMPLETE LOSS OF FUNCTION AT BASELINE Paris, 27 April , 202 3 , 8 .30 pm CET AB Science SA (Euronext – FR0010557264 – AB) today summarizes the presentation that was made on masitinib in amyotrophic lateral sclerosis (ALS) at the American Academy...
PRESS RELEASE SUCCESS OF THE CAPITAL INCREASE BY PRIVATE PLACEMENT FOR AN AMOUNT OF 15 MILLION EUROS Paris, April 24 , 2023, 8am CET AB Science S.A. (the “ Company ” or “ AB Science ”, NYSE Euronext – FR0010557264 – AB), announces today the success of its capital increase through the issuance of new ordinary shares with attached warrants, with a waiver of preferential subscription rights, via a private placement for a final amount of 15.0 million euros (the “ Capital Increase ”)....
PRESS RELEASE AB SCIENCE ANNOUNCES MASITINIB PATENT GRANTED IN JAPAN FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS, S TRENGTHENING THE COMPANY’S INTELLECTUAL PROPERTY POSITION UNTIL 203 7 TO DATE , THIS PATENT HAS BEEN GRANTED IN 12 REGIONS INCLUDING EUROPE, USA , CHINA, ISRAEL AND MOST RECENTLY JAPAN Paris, 18 April , 202 3 , 6 . 45 pm CET AB Science SA (Euronext - FR0010557264 - AB) today announced that the patent office of Japan has issued a Notice of Allowance (NOA) for a patent...
PRESS RELEASE RESULTS OF MASITINIB IN ALS SELECTED FOR A SCIENTIFIC PLATFORM PRESENTATION AT THE AMERICAN ACADEMY OF NEUROLOGY 2023 ANNUAL MEETING , INCLUDING LONG-TERM SURVIVAL ANALYS IS AND NEW ANALYSIS OF PATIENT POPULATION WITH NO COMPLETE LOSS OF FUNCTION AT BASELINE Paris, 12 April , 202 3 , 6 .15 pm CET AB Science SA (Euronext – FR0010557264 – AB) today announced that Professor Albert Ludolph, MD, PhD (Chairman of the Department of Neurology at the University Hospital and Medical...
PRESS RELEASE AB SCIENCE ANNOUNCES THAT IT HAS SUBMITTED ITS RESPONSE TO THE DAY 120 QUESTIONS IN THE EMA REGULATORY REVIEW OF MASITINIB IN AMYO TROPHIC LATERAL SCLEROSIS AND CLARIFIES THE NEW TIMELINE FOR RESPONDING TO HEALTH CANADA Paris, A pril 4 2023, 6pm AB Science S.A. (the " Company " - Euronext - FR0010557264 - AB) today provides an update on the schedule for the evaluation by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) and by Health...
PRESS RELEASE AB SCIENCE REPORTS A FIRST COMPLETE BONE MARROW RESPONSE IN A RELAPSED REFRACTORY ACUTE MYELOID LEUKEMIA ( AML ) PATIENT FROM THE VERY LOW DOSE ARM OF ITS AB8939 PHASE I/II CLINICAL TRIAL (AB18001) AB SCIENCE WILL HOST A LIVE WEBCAST ON ITS NEW MICROTUBULE PLATFORM ON T HURSDAY MARCH 1 6 , 2023, FROM 6PM TO 7PM CET Paris, 13 March , 202 3 , 6pm CET AB Science SA (Euronext – FR0010557264 – AB) today announces a case report from the initial stage of its Phase I/II study (AB18001)...
PRESS RELEASE PUBLICATION OF THE MASITINIB PIVOTAL PHASE 3 CLINICAL TRIAL IN ALZHEIMER'S DISEASE IN THE JOURNAL ALZHEIMER'S RESEARCH & THERAPY Paris, 28 February , 202 3 , 8am CET AB Science SA (Euronext - FR0010557264 - AB) today announced publication of results from its positive pivotal phase 3 trial (AB09004) of masitinib in mild-to-moderate Alzheimer’s disease (AD) in the renowned international peer-reviewed journal Alzheimer's Research & Therapy [1]. This article, titled ‘ Masitinib for...
PRESS RELEASE AB SCIENCE ANNOUNCES THE DRAWDOWN OF THE SECOND TRANCHE OF 6 MILLION EUROS UNDER ITS FINANCING AGREEMENT WITH THE EUROPEAN INVESTMENT BANK Paris, January 31, 2023 , 6pm CET AB Science SA (Euronext - FR0010557264 - AB) announced today that it has received payment of €6.0 million as the second tranche of a €15 million loan from the European Investment Bank (EIB). As previously announced [1], the agreement signed with the EIB provides a financing in two tranches of EUR 6.0 million...
PRESS RELEASE AB SCIENCE HAS RECEIVED APPROVAL FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) TO INITIATE THE CONFIRMATORY PHASE 3 STUDY WITH MASITINIB IN THE TREATMENT OF PROGRESSIVE MULTIPLE SCLEROSIS Paris, December 29 2022, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) announced today that its Phase III clinical trial (AB20009) in progressive forms of multiple sclerosis has been approved by the US Food and Drug Administration (FDA). This decision follows authorizations received from...
PRESS RELEASE MASITINIB RECEIVES ORPHAN DRUG STATUS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN SWITZERLAND Paris, December 27 , 202 2 , 7 pm CET AB Science SA (Euronext - FR0010557264 - AB) today announces that masitinib has been granted orphan drug status (ODS) by the Swiss Agency for Therapeutic Products (Swissmedic) for the treatment of patients with amyotrophic lateral sclerosis (ALS). As a reminder, masitinib has previously received ODS for ALS from the U.S. Food and Drug...
PRESS RELEASE AB SCIENCE ANNOUNCES THE DRAWDOWN OF THE FIRST TRANCHE OF 6 MILLION EUROS UNDER ITS FINANCING AGREEMENT WITH THE EUROPEAN INVESTMENT BANK Paris, December 22 , 2022, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) announced today that it has received payment of €6.0 million as the first tranche of a €15 million loan from the European Investment Bank (EIB). As previously announced [1], the agreement signed with the EIB provides a financing in two tranches of EUR 6.0 million...
PRESS RELEASE AB SCIENCE RECEIVES FIRST AGENCIES AUTHOR I ZATION S TO INITIATE CONFIRMATORY PHASE 3 CLINICAL STUDY WITH MASITINIB IN THE TREATMENT OF ALZHEIMER’S DISEASE Paris, October 10 th 202 2 , 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today announces that the first authorizations have been received to initiate its phase 3 confirmatory study (AB21004) evaluating masitinib in patients with mild to moderate Alzheimer's Disease (AD) from the French Medicine Agency (ANSM) together...
